BOSTON and ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. IKT (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that risvodetinib (IkT-148009) has been…Read More
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy Inhibikase Therapeutics NASDAQIKT
